Clinical Course of Intestinal Behcet’s Disease During the First Five Years

Jung, Yoon Suk; Cheon, Jae Hee; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho

doi:10.1007/s10620-012-2351-9

Cited by 54 publications

(44 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is 1 GI index that was developed and validated specifically for BS (Disease Activity Index for Intestinal Behçet Disease) 211,216,218,220,221 . This index showed a higher correlation with physician global assessment and higher responsiveness than the Crohn Disease Activity Index.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Hatemi

Merkel²,

Hamuryudan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

Behçet syndrome (BS) is a multisystem vasculitis that is most active during young adulthood, causing serious disability and significant impairment in quality of life. Differences in the disease course, severity, and organ involvement between patients, depending on the age at presentation and sex, makes it impossible to determine a single management strategy. The diversity and variability in the outcome measures used in clinical trials in BS makes it difficult to compare the results or inform physicians about the best management strategy for individual patients. There is a large unmet need to determine or develop validated outcome measures for use in clinical trials in BS that are acceptable to researchers and regulatory agencies. We conducted a systematic review to describe the outcomes and outcome measures that have been used in clinical trials in BS. This review revealed the diversity and variability in the outcomes and outcome measures and the lack of standard definitions for most outcomes and rarity of validated outcome tools for disease assessment in BS. This systematic literature review will identify domains and candidate instruments for use in a Delphi exercise, the next step in the development of a core set of outcome measures that are properly validated and widely accepted by the collaboration of researchers from many different regions of the world and from different specialties, including rheumatology, ophthalmology, dermatology, gastroenterology, and neurology.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Erythrocyte sedimentation rate9,16,22,24,34,40,43,47,49,59,60,61,63,66,67,68,69,76,77,85,89,94,139,143,177,220,228 and C-reactive protein9,16,24,40,43,47,49,59,60,66,67,76,77,85,89,94,143,177,216,220,228 levels were used as indicators of disease activity. No laboratory measure has been validated as a biomarker of disease activity in BS.…”

Section: Resultsmentioning

confidence: 99%

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Hatemi

Merkel²,

Hamuryudan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Patients were identified by using the Severance Hospital IBD Clinic Registry, which is an internal web-based electronic medical record system that includes all patients with intestinal BD at Severance Hospital, Yonsei University College of Medicine [13, 14]. This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of Severance Hospital.…”

Section: Methodsmentioning

confidence: 99%

Risk Factors and Outcomes of Emergency Room Visits in Intestinal Behçet’s Disease

Park¹,

Cheon

Park

et al. 2017

Digestion

View full text Add to dashboard Cite

Background/Aims: Intestinal Behçet’s disease (BD) is a chronic recurring intestinal vasculitic disorder that can lead to emergency room (ER) visits. We aimed to investigate the independent risk factors associated with intestinal BD-related ER visits. Methods: We retrospectively reviewed 606 patients with intestinal BD registered at the Inflammatory Bowel Disease Clinic of Severance Hospital, Seoul, Korea. Results: One hundred eighty-five patients (30.5%) visited the ER at least once (total visits, 510). In multivariate analysis, lower socioeconomic status (hazard ratio [HR] 1.884), higher comorbidity index (HR 1.548), corticosteroid use (HR 1.459), higher C-reactive protein (CRP; HR 1.375), and higher disease activity index for intestinal BD (DAIBD) score (HR 1.013) were independent risk factors. However, older age (HR 0.982), disease duration (HR 0.850), opioid use (HR 0.528), and higher hemoglobin level (HR 0.944) were significantly associated with decreased ER visits. Conclusions: The ER attendance rate of patients with intestinal BD was 30.5%. Lower socioeconomic status, higher comorbidity index, corticosteroid use, higher CRP, and higher DAIBD score were positively associated with ER visits. Older age, disease duration, opioid use, and higher hemoglobin level were significantly associated with decreased ER visits.

show abstract

“…Recently, there was a retrospective analysis from a single centre about their results of the treatment of gastrointestinal BD with 5-ASA/SSZ, corticosteroids only, AZA/6-mercaptopurine (6-MP), or IFX, Surgery was also evaluated [51]. Ninety-three patients with a mild clinical course and 37 with a severe clinical course were analysed.…”

Section: Gastrointestinal Involvementmentioning

confidence: 99%

The challenging treatment of Behcet’s disease

Kötter¹

2015

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Clinical Course of Intestinal Behcet’s Disease During the First Five Years

Cited by 54 publications

References 22 publications

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Risk Factors and Outcomes of Emergency Room Visits in Intestinal Behçet’s Disease

The challenging treatment of Behcet’s disease

Contact Info

Product

Resources

About